Make sure you meet both the case minimum requirement (usually 20 patients) and the 70%-data completeness criteria when reporting a MIPS quality measure in 2023.
Explore TEPEZZA® (teprotumumab-trbw) now for your patients with this serious, progressive disease.
TEPEZZA is a trademark owned by or licensed to Horizon.© 2022 Horizon Therapeutics plc P-TEP-US-00805 12/22
Public & Patients
Museum of the Eye